Edition:
India

People: Biomarin Pharmaceutical Inc (BMRN.OQ)

BMRN.OQ on NASDAQ Stock Exchange Global Select Market

76.51USD
20 Aug 2019
Change (% chg)

-- (--)
Prev Close
$76.51
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
457,193
52-wk High
$106.69
52-wk Low
$71.56

Lawlis, V. Bryan 

Dr. V. Bryan Lawlis, Jr., Ph.D., is an Independent Director of Biomarin Pharmaceutical Inc. Dr. Lawlis joined our Board in June 2007. From August 2011 to September 2017 he served as the President and Chief Executive Officer of Itero Biopharmaceuticals, LLC, a private holding company that held the assets of Itero Biopharmaceuticals, Inc, a private biotechnology company. Dr. Lawlis co-founded and served as President and Chief Executive Officer of Itero Biopharmaceuticals, Inc. from 2006 until it discontinued operations in August 2011. Dr. Lawlis served as President and Chief Executive Officer of Aradigm Corporation (Aradigm), a pharmaceutical company, from August 2004 to August 2006, and served on its board from February 2005 to August 2006, continuing in both capacities until August 2006. Dr. Lawlis previously served as Aradigm’s President and Chief Operating Officer from June 2003 to August 2004 and its Chief Operating Officer from November 2001 to June 2003. Prior to his time at Aradigm, Dr. Lawlis co-founded Covance Biotechnology Services, a contract biopharmaceutical manufacturing operation, served as its President and Chief Executive Officer from 1996 to 1999, and served as Chairman from 1999 to 2001, when it was sold to Diosynth RTP, Inc., a division of Akzo Nobel, NV. From 1981 to 1996, Dr. Lawlis was employed at Genencor, Inc., a biotechnology company, and Genentech, Inc. His last position at Genentech, Inc. was Vice President of Process Sciences. Dr. Lawlis has served on the board of Geron Corporation, a public biopharmaceutical company, since March 2012, and has served as a member of the board of Coherus Biosciences, Inc., a public biotechnology company (Coherus), since October 2014. He previously served on the board of KaloBios Pharmaceuticals, Inc., a public biopharmaceutical company, from August 2013 until September 2014, and he acted as the Chairman of the scientific advisory board for Coherus from November 2012 to June 2016. Dr. Lawlis holds board positions at three private companies: AbSci, LLC.

Basic Compensation

Total Annual Compensation, USD --
Restricted Stock Award, USD 183,680
Long-Term Incentive Plans, USD --
All Other, USD 265,715
Fiscal Year Total, USD 449,395

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Jean-Jacques Bienaime

15,917,000

Daniel Spiegelman

4,641,880

Henry Fuchs

7,045,420

G. Eric Davis

2,708,210

Jeff Ajer

4,568,300

Robert Baffi

4,473,230
As Of  31 Dec 2017